OR WAIT null SECS
The company will supply its heparin sodium injection in prefilled syringe form.
London-based Hikma Pharmaceuticals has launched a new prefilled syringe capability in the United States through its affiliate, Hikma Pharmaceuticals USA, the company announced on Sept. 17, 2019. Hikma will supply heparin sodium injection, USP, 5000 units/mL in prefilled syringe form.
Heparin sodium injection is indicated for prophylaxis and treatment of venous thrombosis and pulmonary embolism; prevention of postoperative deep venous thrombosis and pulmonary embolism; atrial fibrillation with embolization; treating acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and cardiac surgery; and prophylaxis and treatment of peripheral arterial embolism. It is also used as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures.
“Medical professionals are always in need of tools that help them improve the speed, safety, and accuracy of patient care, and that is why Hikma is excited to launch our prefilled syringe capability,” said Dan Motto, Hikma’s executive vice-president of Commercial & Business Development, US Injectables, in a company press release. “Our [h]eparin [s]odium [i]njection prefilled syringes are ready-to-administer and will help hospitals, pharmacists, doctors, and nurses treat patients faster, more easily, and with reduced risk.”
“Hikma is continuously expanding its broad and deep portfolio of essential injectable medicines,” said Riad Mishlawi, president, Hikma Injectables, in the press release. “We have made significant investments in our US manufacturing capabilities to bring this new prefilled syringe capability to market, and [h]eparin is the first of many important medicines we will deliver in this form.”
Source: Hikma Pharmaceuticals